Functional Competition between Poly(ADP-ribose) Polymerase and Its 24-kDa Apoptotic Fragment in DNA Repair and Transcription*

Tetsu M. C. Yung and Masahiko S. SatohDagger

From the DNA Repair Group, Health and Environment Unit, Laval University Medical Centre, CHUQ, Faculty of Medicine, Laval University, Ste-Foy, Quebec G1V 4G2, Canada

Received for publication, September 1, 2000, and in revised form, December 12, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Poly(ADP-ribose) polymerase is a 113-kDa nuclear enzyme that binds to both damaged DNA and to RNA associated with actively transcribed regions of chromatin. Binding of poly(ADP-ribose) polymerase to DNA lesions activates it, catalyzing the covalent addition of multiple ADP-ribose polymers to the enzyme (automodification). During apoptosis, poly(ADP-ribose) polymerase is cleaved by caspase-3, resulting in the formation of an N-terminal 24-kDa fragment, containing the DNA binding domain, and a C-terminal 89-kDa catalytic fragment. The functional relevance of this cleavage is not well understood. We therefore prepared a recombinant 24-kDa poly(ADP-ribose) polymerase fragment and investigated the role of this fragment in DNA repair and transcription. The 24-kDa fragment retained its binding affinity for both DNA breaks and RNA. In an in vitro cell-free DNA repair assay, this fragment inhibited rejoining of DNA breaks and suppressed ADP-ribose polymer formation by competing with poly(ADP-ribose) polymerase in binding to DNA breaks. With regard to transcription, it has recently been demonstrated that binding of poly(ADP-ribose) polymerase to transcribed RNA reduces the rate of transcript elongation and that automodification of poly(ADP-ribose) polymerase bound to DNA breaks results in up-regulation of transcription. We tested the 24-kDa fragment for its ability to suppress transcript elongation, and we found that it competed against the up-regulation of transcription mediated by full-length poly(ADP-ribose) polymerase. The ability of the 24-kDa fragment to inhibit DNA repair, ADP-ribose polymer formation, and damage-dependent up-regulation of transcription may contribute to the apoptotic shift from cell survival to cell death mode.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Poly(ADP-ribose) polymerase (PARP)1 is a highly abundant nuclear enzyme present at about 2 × 105 molecules per nucleus (1). This enzyme is composed of an N-terminal DNA binding domain, containing two zinc finger motifs, a C-terminal NAD+ binding domain, catalyzing the synthesis of ADP-ribose polymers from its substrate, NAD+, and an automodification site, which unites the N-terminal and C-terminal domains (2). Poly(ADP-ribosyl)ation by PARP at the automodification site of the protein is initiated by the binding of the zinc fingers to DNA breaks (3, 4). As a consequence of this automodification, the binding affinity of PARP for DNA is reduced, resulting in dissociation of PARP from DNA breaks (5) and thereby allowing the DNA repair machinery to access the sites of DNA damage (6).

In cells where DNA breaks are generated by DNA-damaging agents, PARP is activated and automodified (3, 4), leading to the conclusion that PARP is involved in the cellular response to genetic damage, particularly in the repair of damaged DNA (3). However, PARP has been shown to lack DNA repair activity in itself (6, 7). Alternatively, it has been suggested that PARP is involved in chromatin stabilization (8), in DNA replication (9, 10), and in transcription (11-13), although the roles played by PARP in these processes are not yet understood.

In nuclear localization experiments, PARP is observed in clear foci, associated both with regions of chromatin actively transcribed by RNA polymerase II as well as with nucleoli where rRNA is synthesized by RNA polymerase I (14). Dispersal of the foci upon treatment of cells with the transcription inhibitors actinomycin D or 5,6-dichloro-1-beta -ribofuranosylbenzimidazole suggests an involvement of PARP in transcription (15). In addition, such foci are also dispersed by treatment of isolated nuclei with RNase (16). These observations thus suggest an interaction between PARP and transcribed RNA. Recently, we demonstrated that RNA-bound PARP reduces the rate of RNA elongation by RNA polymerase II and that automodification of PARP in response to DNA damage up-regulates transcription (17). Since DNA-damaging agents induce RNA damage as well, we proposed that this up-regulation allows cells to compensate for the loss of damaged RNA that occurs collaterally with DNA damage and that this pathway is required for cell survival following exposure to DNA-damaging agents (17).

When cells are exposed to sufficiently high levels of DNA-damaging agents, they commit to cell death by inducing either apoptosis or necrosis. During apoptosis PARP is cleaved by the apoptosis-specific protease, caspase-3, resulting in the formation of an N-terminal 24-kDa fragment, containing the DNA binding domain, and a C-terminal 89-kDa catalytic domain, containing the automodification site (18-20). Recently, Halappanavar et al. (21) and Oliver et al. (22) reported that, in PARP knockout cells, expression of uncleavable PARP, lacking the caspase-3 recognition sequence, causes delayed induction of DNA damage-induced apoptosis. This observation suggests that cleavage of PARP has a role in damage-induced apoptosis. In addition, Herceg and Wang (23) and Boulares et al. (24) suggested that cleavage of PARP is also required for tumor necrosis factor-alpha -induced cell death. However Herceg and Wang (23) found increased cell death by necrosis, whereas Boulares et al. (24) demonstrated a promotion of apoptotic, rather than necrotic, cell death by expressing uncleavable PARP in PARP knockout cells.

Since the 24-kDa fragment contains the DNA binding domain, which is capable of binding to DNA breaks (25), it has been speculated that the 24-kDa fragment possibly counteracts functions of PARP and promotes the process of apoptosis (19). However, biochemical characteristics of the 24-kDa fragment remain to be elucidated. Thus, we prepared the 24-kDa apoptotic fragment of PARP and asked whether the 24-kDa fragment competes against the functions of PARP in DNA repair, ADP-ribose polymer formation, and transcription.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cell Line and Antibody-- GMO1953A lymphoblastoid cells were obtained from NIGMS Human Mutant Cell Repository (Camden, NJ). The C-II-10 antibody against the automodification domain of PARP and the F1-23 antibody against the DNA binding domain of PARP (zinc finger 2) (26) were kindly provided by Dr. G. G. Poirier.

Expression of Recombinant PARP and the 24-kDa Fragment-- Full-length PARP cDNA (bases 1-3039) or the sequence corresponding to the 24-kDa DNA binding domain of PARP (bases 1-654), which is found in apoptotic cells (18-20), was cloned into pET3a (Novagen) and used to transform HMS 174 de3 cells (Novagen) together with pLysE (Novagen). After overnight pre-culture, the Escherichia coli were propagated in 2 liters of Luria-Bertani medium in the presence of 34 µg/ml chloramphenicol and 100 µg/ml ampicillin for 3 h, and expression of PARP or the 24-kDa fragment was induced in the presence of 0.4 mM isopropyl-beta -D-thiogalactoside for 3 h at 37 °C. The bacteria were then spun down at 3500 × g for 10 min, and the pellet was washed in phosphate-buffered saline and spun down. The resulting pellet was resuspended in 20 ml of buffer containing 0.1 M NaCl, 50 mM Tris-HCl, pH 8.0, 12% glycerol, 2 mM MgCl2, and 0.1 mM phenylmethylsulfonyl fluoride (Buffer CB), and PARP or the 24-kDa fragment was extracted by sonication. After a 30-min centrifugation at 35,000 × g (at 4 °C), the supernatant was used for purification of PARP or the 24-kDa fragment.

Purification of PARP-- E. coli lysate (750 mg) was applied to a phosphocellulose column (10 mm diameter and 2-ml bed volume) equilibrated with Buffer CB. PARP was eluted using a linear gradient of Buffer CB containing 0.1-2.0 M NaCl. The fractions of interest were determined by silver stain analysis of samples run on SDS-12.5% polyacrylamide gels. The fractions of interest were then pooled, diluted with Buffer CB to reduce the NaCl concentration below 0.2 M, and applied to a DNA cellulose column (5 mm diameter and 2-ml bed volume) equilibrated with Buffer CB. After washing the column with 20 ml of Buffer CB followed by 8 ml of Buffer CB containing 0.4 M NaCl, PARP was eluted with 8 ml of Buffer CB containing 1.0 M NaCl. The eluate was diluted with Buffer CB to reduce the NaCl concentration below 0.2 M and applied to a heparin-Sepharose column (Amersham Pharmacia Biotech, Hi-Trap, 5 ml) equilibrated with Buffer CB. PARP was eluted using a linear gradient of Buffer CB containing 0.1-2.0 M NaCl, and the final fractions were dialyzed against Buffer CB prior to analysis.

Purification of the 24-kDa Fragment-- Purification was carried out as for PARP except that the DNA cellulose chromatography was omitted. The final preparation was dialyzed against Buffer CB prior to analysis.

Quantitation of PARP and the 24-kDa Fragment by Direct ELISA-- The purified recombinant PARP and the 24-kDa fragment were quantified by direct ELISA. Briefly, PARP and the 24-kDa fragment were immobilized on a microtiter plate, treated with the antibody F1-23 (26) (5000-fold dilution) which recognizes the zinc finger 2 motif present in both PARP and the 24-kDa fragment, and then treated with secondary antibody conjugated to horseradish peroxidase. Following addition of TMB substrate (Research Diagnostics Inc.), 0.18 M H2SO4 was used to initiate the peroxidase reaction. PARP and the 24-kDa fragment were quantified based on absorbance at 490 nm.

Gel Retardation Assay (DNA)-- To prepare the DNA probe for the gel retardation assay, a single-stranded 50-base oligodeoxynucleotide (100 pmol) was 32P-labeled at 37 °C for 15 min using 25 µCi of [gamma -32P]ATP with 10 units of T4 polynucleotide kinase (Amersham Pharmacia Biotech) in a 25-µl reaction mixture using the buffer provided by the supplier. The labeled single-stranded oligodeoxynucleotide was annealed with its complementary single-stranded oligodeoxynucleotide (50 bases) in a 100-µl mixture containing 10 mM Tris-HCl, pH 8.0, and 1 mM EDTA by incubating for 5 min at 95 °C, followed by 5 min at 50 °C, and then 20 min at 22 °C. The annealed double-stranded oligodeoxynucleotide was then precipitated with ethanol and ammonium acetate, and the resulting pellet was dissolved in 10 mM Tris-HCl, pH 8.0, and 1 mM EDTA. The binding reaction was carried out using 1 pmol of the 32P-labeled double-stranded oligodeoxynucleotide with varying amounts of PARP or the 24-kDa fragment in a buffer containing 5 mM Tris-HCl, pH 8.0, and 5 mM MgCl2 for 15 min at 30 °C in a 15-µl reaction mixture. Samples were then fractionated by native 6% polyacrylamide gel electrophoresis, and the gel was dried and exposed to x-ray film for autoradiography or used for quantitation by AlphaImager (Packard Instrument Co.).

Gel Retardation Assay (RNA)-- Gel retardation assays using an RNA probe were carried out as described previously (17). Briefly, 32P-labeled stem-loop RNA was synthesized using T3 RNA polymerase to transcribe the human immunodeficiency virus, type I TAR sequence. The 32P-labeled stem-loop RNA was then incubated with PARP or the 24-kDa fragment and fractionated by native 6% polyacrylamide gel electrophoresis. After drying, the gel was either exposed to x-ray film for autoradiography or used for quantitation by AlphaImager (Packard Instrument Co.).

Cell-free DNA Repair Assay-- Cell-free extracts were prepared from GMO1953A lymphoblastoid cells following the method of Manley et al. (27). The cell-free DNA repair assay was carried out using 50 µg of extract, 300 ng of gamma -irradiated pBluescript II KS+ (pBS, 3 kilobase pairs) containing an average of one single-stranded DNA break per molecule (6), and varying amounts of the 24-kDa fragment in the presence or absence of 2 mM NAD+ under reaction conditions described previously (28). After purification of the DNA, unrepaired pBS (open circular) and repaired pBS (closed circular) were resolved by ethidium bromide, 1% agarose gel electrophoresis.

Analysis of Poly(ADP-ribosyl)ation-- To determine the amount of ADP-ribose polymers produced in the cell-free DNA repair assay, 1.3 µCi of [32P]NAD+ and 0.25 mM NAD+ were added to the reaction described above. Reactions were terminated by addition of trichloroacetic acid, and insoluble 32P activity retained on a GF/C filter was counted as described previously (28).

Pulse-Chase Elongation Assay-- Pulse-chase elongation assays were carried out as described previously (17). Briefly, a pGf1 plasmid containing a G-less sequence was digested with PacI, creating a 90-base G-less sequence at one end of the DNA. A C-tail was added to allow loading of RNA polymerase II from DNA break ends. The DNA was then incubated with RNA polymerase II (1.0 units) (provided by Dr. H. Serizawa) (29) in the presence of RNasin, ATP, UTP, CTP, and [alpha -32P]CTP at 37 °C for 30 min as described by Shilatifard et al. (30). A chase was initiated by addition of GTP and excess CTP in the presence or absence of PARP or the 24-kDa fragment. After extraction and precipitation, RNA was fractionated on a 6% polyacrylamide, M urea gel. After drying, the gel was exposed to x-ray film for autoradiography.

Cell-free Transcription Assay-- pCMV-Luc containing the cytomegalovirus promoter was linearized by ScaI restriction digestion and used in a run-off transcription assay with HeLa nuclear extracts (Promega). The expected size of the run-off product was 400 bases. Reactions were carried out for 1 h at 30 °C using 4 µg/ml linearized pCMV-Luc in a reaction mixture containing 10 mM HEPES-KOH, pH 7.9, 40 mM KCl, 0.2 mM dithiothreitol, 3 mM MgCl2, 400 µCi/ml [alpha -32P]GTP, 400 µM ATP, 400 µM CTP, 400 µM UTP, 16 µM GTP, 10% glycerol, 1000 transcription units/ml of HeLa nuclear extract, and varying amounts of either PARP or the 24-kDa fragment. The reaction was terminated by addition of 7 volumes of 0.3 M Tris-HCl, pH 7.4, 0.3 M sodium acetate, 0.5% SDS, 2 mM EDTA, and 3 µg/ml tRNA. Following phenol/chloroform extraction, transcripts were precipitated with ethanol, fractionated by 3% polyacrylamide, 8 M urea gel electrophoresis, and visualized by autoradiography.

Apoptosis Induction and TUNEL Assay-- The mammalian expression vector pcDNA 3.1- (Invitrogen) was used to clone the cDNA corresponding to the 24-kDa DNA binding domain of PARP (pcDNA 3.1-/AF24). Then 1.25 µg/ml pcDNA3.1-/AF24 was incubated with 3.75 µl/ml Tfx20TM reagent (Promega) in serum-free Dulbecco's modified Eagle's medium (serum-free DMEM) for 10 min at room temperature and used to treat HeLa S3 cells (attached to coverslips) for 1 h at 37 °C. Following cell treatment, DMEM containing 10% fetal bovine serum and antibiotics (complete DMEM) was added; HeLa S3 cells were cultured for 24 h after which the medium was replaced with serum-free DMEM, and the cells were exposed to N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) (50 µM). After 20 min of treatment at 37 °C, the medium was replaced with complete DMEM, and cells were cultured for 2 h. TUNEL staining (fluorescein in situ cell death detection kit, Roche Molecular Biochemicals) was then carried out after fixing the cells in 3% paraformaldehyde and permeabilizing them with 0.1% Triton X-100 and 0.1% sodium citrate according to the supplier's instructions (Roche Molecular Biochemicals). TUNEL-positive cells were visualized by fluorescence microscopy.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Recombinant PARP and the 24-kDa Fragment-- To investigate the effect of the 24-kDa PARP fragment on DNA repair and transcription, we first prepared the recombinant 24-kDa fragment and full-length PARP. As shown in Fig. 1, the 24-kDa fragment, which migrated to an apparent molecular mass of about 30 kDa on SDS-polyacrylamide gels, was purified to over 99% homogeneity as described under "Materials and Methods". The purity of full-length recombinant PARP was about 95%, with several truncated products observed (Fig. 1). Quantitation of the 24-kDa fragment and PARP was carried out by direct ELISA using the F1-23 antibody (26), which recognizes the zinc finger 2 motif of PARP and the 24-kDa fragment.



View larger version (11K):
[in this window]
[in a new window]
 
Fig. 1.   Purified recombinant 24-kDa fragment and PARP. Recombinant 24-kDa fragment and PARP were purified as described under "Materials and Methods," fractionated by SDS-12.5% polyacrylamide gel electrophoresis, and visualized by silver staining.

Binding of the 24-kDa Fragment and PARP to DNA Breaks-- 32P-Labeled double-stranded oligodeoxynucleotide (50 base pairs) was incubated with either the 24-kDa fragment or PARP. If the zinc finger motifs found in PARP and the 24-kDa fragment bind to DNA ends (2, 31), the mobility of the 32P-labeled DNA probe should be reduced on a native gel. As shown in Fig. 2, discrete retarded bands were in fact observed when the labeled probe was incubated with the 24-kDa fragment. Migration of the probe was similarly retarded when PARP was used instead of the 24-kDa fragment, with the probe migrating slightly more slowly than in the case of the 24-kDa fragment. In addition, the labeled probe was reproducibly found at the origin of the lane. Addition of excess unlabeled double-stranded oligodeoxynucleotide inhibited retardation of the probe, confirming that formation of the retarded labeled material was due to binding of the 24-kDa fragment or PARP to the DNA probe (data not shown). The data in Fig. 2 reveal a linear relationship between 32P activity associated with the retarded fractions and the amount of the 24-kDa fragment or PARP and allow us to determine that the 24-kDa fragment has about 25% of the binding activity of full-length PARP. Thus, even after cleavage of PARP by caspase-3, the resulting 24-kDa fragment retains significant DNA binding activity.



View larger version (30K):
[in this window]
[in a new window]
 
Fig. 2.   Gel retardation assay (DNA). Recombinant 24-kDa fragment or PARP was incubated with 32P-labeled 50-base pair double-stranded DNA probe, and the DNA was then fractionated on a native 6% polyacrylamide gel. The 32P activity was visualized by autoradiography, and the 32P activity in the retarded fraction (including origin) was quantified with InstantImager (Packard Instrument Co.); relative activity is shown (arbitrary units).

Inhibition of DNA Repair by the 24-kDa Fragment-- In the absence of PARP's substrate, NAD+, PARP binds to and persists on DNA breaks, thereby inhibiting DNA repair (6). Thus, dissociation of PARP from DNA breaks by automodification is a prerequisite for DNA repair (6). Since the 24-kDa fragment is capable of binding to DNA breaks (Fig. 2) but lacks the automodification site, these fragments should persist on DNA breaks and inhibit DNA repair even in the presence of NAD+. To test this hypothesis, a cell-free DNA repair assay was carried out using open circular pBS containing gamma -ray-induced single-stranded DNA breaks, cell-free extracts, and varying amounts of the 24-kDa fragment in the presence or absence of NAD+. As shown in Fig. 3, only 7% of DNA breaks were rejoined in the absence of NAD+ due to inhibition of DNA repair by bound PARP. By contrast, when poly(ADP-ribosyl)ation and dissociation of PARP from DNA breaks was initiated by addition of NAD+, about 30% of DNA breaks were repaired. This NAD+-promoted DNA repair was significantly inhibited by addition of the 24-kDa fragment (Fig. 3, A and B). A 6.6-fold molar excess of the 24-kDa fragment relative to PARP was sufficient to inhibit NAD+-promoted DNA repair by 80% (Fig. 3, A and B, 15 pmol of PARP derived from extract versus 100 pmol of the 24-kDa fragment), consistent with the hypothesis that the 24-kDa fragment, unlike full-length PARP, binds to and persists on DNA breaks in the presence of NAD+.



View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   Cell-free DNA repair assay and reduced synthesis of ADP-ribose polymers in the presence of the 24-kDa fragment. A, cell-free reactions were carried out in the presence or absence of NAD+ using varying amounts of the 24-kDa fragment and damaged pBS (open circular, OC) containing gamma -ray-induced single-stranded DNA breaks in a 50-µl reaction mixture (see "Materials and Methods"). The DNA was then purified, and damaged pBS was separated from repaired closed circular pBS by ethidium bromide, 1% agarose gel electrophoresis to determine the amount of repaired plasmid. The relative proportions of the 24-kDa fragment and PARP (15 pmol derived from cell-free extracts) are also shown. B, repaired DNA (closed circular, CC) expressed as a percentage of total DNA. C, cell-free DNA repair reactions were carried out using varying amounts of the 24-kDa fragment (0 pmol (black-down-triangle ), 50 pmol (black-triangle), or 200 pmol (black-diamond )) and pBS containing gamma -ray-induced single-stranded DNA breaks in the presence of 0.25 mM NAD+ and 1.3 µCi of [32P]NAD+ in a 50-µl reaction mixture. Reactions were also carried out using undamaged pBS (). The 32P-labeled protein was then trapped onto glass fiber filters, and the radioactivity was counted to determine the amount of ADP-ribose polymers synthesized during the reaction as described under "Materials and Methods." The ratios between 0, 50, and 200 pmol of the 24-kDa fragment to PARP (15 pmol derived from cell-free extracts) were 0, 3.6 and 13.3, respectively.

We then measured the amount of ADP-ribose polymers generated in the cell-free assay in the absence or presence of the recombinant 24-kDa fragment. As previously observed (28), incubation of cell-free extracts with DNA breaks caused transient formation of ADP-ribose polymers (Fig. 3C). However, addition of the 24-kDa fragment significantly inhibited ADP-ribose polymer formation, suggesting that the 24-kDa fragment effectively competed with PARP in binding to DNA breaks and thereby reduced the overall level of poly(ADP-ribosyl)ation in the presence of NAD+.

Since ADP-ribose polymers are synthesized from NAD+, inhibition of poly(ADP-ribose) formation should reduce the consumption of NAD+. To quantify the amount of NAD+ present in the reaction mixture following the cell-free DNA repair assay, [32P]NAD+ (32 nM) was added to the assay and the reaction mixtures were applied to a 20% polyacrylamide, 8 M urea gel (32) for quantification of labeled NAD+. Activation of PARP consumed 20% of the available NAD+, whereas addition of the 24-kDa fragment (200 pmol) resulted in only a negligible reduction in NAD+ levels (data not shown).

Taken together, these results suggest that the 24-kDa fragment inhibits DNA repair and ADP-ribose formation by binding to and persisting on DNA breaks in competition with full-length PARP.

Binding of the 24-kDa Fragment to RNA Stem-Loop-- In nuclei, PARP has been observed to associate with chromatin, particularly with actively transcribed regions; this association has been shown to occur by direct binding of PARP to transcribed RNA (14-16). We recently demonstrated that binding of PARP to RNA stem-loop structures reduces the rate of RNA elongation by RNA polymerase II and that formation of DNA breaks and subsequent automodification of PARP removes the transcriptionally inhibitory PARP molecules, thus up-regulating RNA synthesis (17).

To investigate whether the 24-kDa fragment binds to RNA stem-loops, uniformly 32P-labeled synthetic stem-loop RNA was prepared by transcribing the TAR sequence from human immunodeficiency virus, type I (see "Materials and Methods"), and was mixed with either the 24-kDa fragment or PARP. As shown in Fig. 4, PARP reduced the mobility of stem-loop RNA on a native polyacrylamide gel, generating a discrete band. The 24-kDa fragment also reduced the mobility of TAR stem-loop RNA (Fig. 4), suggesting that the fragment, like full-length PARP, is capable of binding to RNA stem-loops. The data in Fig. 4 reveal a linear relationship between 32P activity associated with the retarded fractions and the amount of 24-kDa fragment or PARP, enabling us to conclude that the 24-kDa fragment has about 15% of the binding activity of full-length PARP.



View larger version (50K):
[in this window]
[in a new window]
 
Fig. 4.   Binding of the 24-kDa fragment and PARP to RNA stem-loops. Recombinant PARP or the 24-kDa fragment was incubated with 5 fmol of 32P-labeled TAR stem-loop RNA for 20 min at 37 °C in a 20-µl reaction mixture. The samples were applied to native 6% polyacrylamide gels. The 32P activity was visualized by autoradiography, and the 32P activity in the retarded fraction was quantified with InstantImager (Packard); relative activity is shown (arbitrary units).

Suppression of Transcript Elongation by the 24-kDa Fragment-- We then tested whether the 24-kDa fragment was capable of reducing elongation of RNA transcripts using a reconstituted pulse-chase elongation assay. Linearized pDelta Gf1, with a 90-base G-less sequence at one end, was prepared (17) and used as a template. During the pulse, RNA polymerase II was loaded onto linearized pDelta Gf1 from the end where the G-less sequence was located and allowed to transcribe the G-less sequence in the absence of GTP but in the presence of ATP, UTP, CTP, and [alpha -32P]CTP, resulting in the formation of 32P-labeled 90-base transcripts (Fig. 5A). The chase was initiated by adding GTP, excess unlabeled CTP, and either the 24-kDa fragment or PARP. As shown in Fig. 5A, the formation of discrete labeled transcripts generated by pausing of RNA polymerase II at putative pause sites was used to follow transcript elongation. Consistent with our previous report showing that PARP suppresses transcript elongation (17), addition of PARP inhibited the production of longer transcripts (Fig. 5A). The addition of the 24-kDa fragment likewise resulted in fewer of the longer transcripts (Fig. 5A), suggesting that the 24-kDa fragment also acted to suppress RNA synthesis by RNA polymerase II.



View larger version (50K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of the 24-kDa fragment on transcription. A, pulse-chase transcription assay was carried out with purified RNA polymerase II as described under "Materials and Methods." During the pulse, RNA polymerase II was loaded onto a G-less sequence located at one end of the linear template in the presence of [alpha -32P]CTP, CTP, ATP, and UTP but not GTP. RNA polymerase stalls at the first G, generating a 90-base transcript. The chase was initiated by adding excess CTP and GTP in the presence of the 24-kDa fragment (1 pmol) or PARP (0.1 pmol). Samples were applied to a 6% acrylamide, 8 M urea gel, and transcripts were visualized by autoradiography. B, a cell-free run-off transcription assay was carried out for 1 h at 30 °C with HeLa nuclear extracts and the 24-kDa fragment in the presence or absence of 0.25 mM NAD+ in a 10-µl reaction mixture. Transcripts were then fractionated on a 3% polyacrylamide, 8 M urea gel, and the gel was exposed to x-ray film to visualize the 400-base run-off transcripts. The relative proportions of the 24-kDa fragment and PARP (2 pmol derived from HeLa nuclear extracts) are also shown. C, produced run-off transcripts expressed in arbitrary units.

RNA stem-loop structures have been demonstrated to result in pausing of RNA polymerase II during transcription (33). In our previous report (17), we suggested that the reduced rate of transcript elongation in the presence of PARP occurs as the result of PARP binding to and stabilizing these stem-loop structures. Upon DNA damage, automodification of PARP promotes the resolution of PARP-RNA complexes, thereby up-regulating transcription (17). On the other hand, the 24-kDa fragment lacks the automodification site and may therefore compete with full-length PARP and inhibit its ability to up-regulate transcription downstream of DNA damage. To test this hypothesis, we carried out run-off transcription assays using HeLa nuclear extracts in the presence or absence of the 24-kDa fragment. Reactions were carried out using 1.8 transcription units of HeLa nuclear extract that contained about 2 pmol of PARP. As shown in Fig. 5B, run-off transcripts 400 bases long were produced from linearized pCMV-Luc. Upon addition of NAD+, PARP that was bound to the ends of linearized template DNA became automodified, and an increase in transcripts was observed, consistent with our previous report (17). However, the addition of the 24-kDa fragment to the run-off reactions (i.e. in addition to PARP and NAD+) resulted in the production of fewer transcripts (Fig. 5B). A 15-fold molar excess of the 24-kDa fragment relative to PARP was sufficient to reduce the NAD+-promoted transcription by 80% (Fig. 5, B and C, 2 pmol of PARP derived from HeLa nuclear extracts versus 30 pmol of the 24-kDa fragment), indicating that these fragments in fact inhibit PARP-mediated up-regulation of RNA synthesis.

Increased Induction of Apoptosis in Cells Expressing the 24-kDa Fragment-- To investigate whether expression of the 24-kDa fragment biases cells toward apoptosis, HeLa S3 cells were transiently transfected with pcDNA 3.1-/AF24 for 24 h. The transfected cells were exposed to 50 µM MNNG for 20 min and then incubated in nomal medium for an additional 2 h, after which apoptosis was analyzed by TUNEL assay. Control cells were transfected with pCMV-Luc for expression of luciferase. As shown in Fig. 6, B and F, only a few TUNEL signals were detected in nontreated cells. On the other hand, we found increased TUNEL signals following MNNG treatment of HeLa S3 cells transfected with pCMV-Luc (Fig. 6D, 39% positive cells). Cells transfected with pcDNA 3.1-/AF24 and treated with MNNG showed a further and dramatic increase in such TUNEL signals (Fig. 6H, 76% positive cells).



View larger version (47K):
[in this window]
[in a new window]
 
Fig. 6.   Increased induction of apoptosis by expression of the 24-kDa fragment. Plasmids containing cDNA for the 24-kDa fragment (frames E-H) or control plasmids containing luciferase cDNA (frames A-D) were transfected into HeLa S3 cells. The cells were then incubated in serum-free DMEM in the presence (C, D, G, and H) or absence (A, B, E, and F) of 50 µM MNNG for 20 min, and apoptotic cells were analyzed by TUNEL assay after 2 h of incubation in normal medium. TUNEL-positive signals were then visualized by fluorescence microscopy (B, D, F, and H). The number in each frame represents the percentage of TUNEL-positive cells among 300 cells analyzed. Phase contrast images are also shown (A, C, E, and G).

Quantitative Western blotting of transfected cells (using either the C-II-10 monoclonal antibody, which recognizes the automodification domain of PARP, or the F1-23 antibody against zinc finger 2 of both PARP and the 24-kDa fragment (26)) revealed a PARP concentration of 28 fmol per 1 × 104 cells versus 180 pmol of the 24-kDa fragment per 1 × 104 cells. Since the transfection efficiency was estimated to be greater than 90% (as determined by the number of green fluorescent cells following transfection with pcDNA 3.1-/GFP), we calculated that the ratio of 24-kDa fragment to PARP in HeLa S3 cells expressing the 24-kDa fragment was 7:1. This ratio appears sufficient, therefore, to sensitize cells to the apoptotic effects of MNNG.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

During apoptosis, the abundant nuclear enzyme PARP is cleaved by caspase-3, generating a 24-kDa fragment containing the DNA binding domain (18-20). In this report, we have demonstrated that the 24-kDa fragment, like full-length PARP, is capable of binding to both DNA breaks and RNA, although the affinity of the 24-kDa fragment for DNA breaks and RNA was reduced to 25 and 15% relative to full-length PARP, respectively. However, given the high affinity of PARP for DNA breaks (31) and RNA (34), the reduced affinity is still significant and consistent with a functional role for the 24-kDa fragment in apoptosis.

Since apoptosis can be induced in PARP knockout cells (35-37), cleavage of PARP may not be required for apoptosis per se. However, it has been suggested that PARP functions to bias cells toward survival (21, 37, 38). If so, then a reduction in the level of full-length PARP as a consequence of cleavage by caspase-3 may counter this normal bias. In addition, the fact that the resulting 24-kDa fragment retains the DNA binding domain of PARP but lacks the automodification site may enable it to act as a dominant negative factor in relation to full-length PARP, since automodification regulates both the DNA binding activity and its poly(ADP-ribosyl)ation activity of PARP (5). In fact, we have demonstrated here that the 24-kDa fragment inhibited DNA repair, ADP-ribose polymer formation, and damage-dependent up-regulation of transcription mediated by PARP, all of which could shift the cell bias from survival to death through apoptosis.

Inhibition of DNA repair by the 24-kDa fragment can be accounted for by the fact that the 24-kDa fragment, unlike full-length PARP molecules, persists on DNA breaks, thus preventing DNA repair enzymes from gaining access to sites of damage. DNA repair can similarly be inhibited under conditions where PARP automodification is suppressed (6), since automodification is essential for driving the dissociation of PARP from DNA breaks. Alternatively, overexpression in mammalian cells of a 42-kDa PARP fragment containing the DNA binding domain and automodification site but lacking the catalytic domain also inhibits DNA repair due to persistence of the 42-kDa fragments on DNA breaks (39). As expected, such inhibition increases the sensitivity of cells to DNA-damaging agents (3, 39). Thus, inhibition of DNA repair by binding of the 24-kDa fragment to DNA breaks may also sensitize cells to DNA-damaging agents.

Binding of the 24-kDa fragment to DNA breaks reduced the formation of ADP-ribose polymers (Fig. 3C) and consequently the consumption of NAD+ (data not shown). It has been suggested that depletion of NAD+ by activation of PARP results in the reduced rate of ATP synthesis and causes cell death by necrosis (23, 40-43). In fact, prevention of NAD+ and ATP depletion stimulates apoptosis and suppresses induction of necrosis (23, 41-43). Consistent with these observations, our biochemical results also support the possibility that the 24-kDa fragment allows cells to enter an apoptotic, rather than necrotic, pathway by preventing over-consumption of NAD+.

The 24-kDa fragment caused inhibition of PARP-mediated up-regulation of transcription (Fig. 5). We recently reported that PARP reduces the rate of transcript elongation by RNA polymerase II and that activation and automodification of PARP, as occurs in response to DNA damage, relieve this inhibition, thereby resulting in up-regulation of transcription (17). Since DNA-damaging agents induce RNA damage as well, we proposed that such up-regulation allows cells to compensate for the collateral loss of RNA following exposure to DNA-damaging agents, and that this pathway is likely required for cell survival. The inhibition of such a regulatory pathway by the 24-kDa PARP fragment may therefore sensitize cells to DNA-damaging agents.

Following expression of the 24-kDa fragment in HeLa cells, Kim et al. (43) found a 50% reduction in ADP-ribose polymer synthesis after exposure of the cells to UV light, as well as increased induction of apoptosis. In the biochemical analysis reported here, a 50% reduction in ADP-ribose polymer formation occurred in the presence of about 120 pmol of the 24-kDa fragment (based on data in Fig. 3C) or about an 8-fold excess of 24-kDa fragment relative to full-length PARP (15 pmol per reaction). In addition, consistent with the report from Kim et al. (43), we also found increased induction of apoptosis by MNNG in HeLa cells expressing a 7-fold excess of 24-kDa fragment relative to full-length PARP (Fig. 6). Furthermore, our biochemical analysis shows that addition of a 7-fold excess of 24-kDa fragment relative to full-length PARP inhibited both NAD+-promoted DNA repair (see Fig. 3B, 15 pmol of full-length PARP derived from cell-free extracts versus 100 pmol of the 24-kDa fragment) and PARP-mediated up-regulation of transcription (see Fig. 5C, 2 pmol of full-length PARP derived from HeLa nuclear extracts versus 13 pmol of the 24-kDa fragment) by 80 and 60%, respectively. Thus, the 24-kDa fragment, by competing with and acting in opposition to PARP, may contribute to the process by which cells irreversibly commit to apoptosis (44).


    ACKNOWLEDGEMENTS

We thank G. G. Poirier for providing the C-II-10 and the F1-23 antibodies; C. W. Ward for editing and comments; and Sachiko Sato for technical advice.


    FOOTNOTES

* This work was supported in part by the National Cancer Institute of Canada for the Terry Fox Run and the Canadian Institutes of Health Research; The Canada Foundation for Innovation and the Quebec government provided infrastructure support.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by a salary support award from the Canadian Institutes of Health Research. To whom correspondence should be addressed: DNA Repair Group, Health and Environment Unit, Laval University Medical Centre, CHUQ, Faculty of Medicine, Laval University, 2705 Blvd. Laurier, Ste-Foy, Quebec G1V 4G2, Canada. Tel.: 418-656-4141 (Ext. 7340); Fax: 418-654-2159; E-mail: Masahiko.sato@crchul.ulaval.ca.

Published, JBC Papers in Press, December 20, 2000, DOI 10.1074/jbc.M008044200


    ABBREVIATIONS

The abbreviations used are: PARP, poly(ADP-ribose) polymerase; MNNG, N-methyl-N'-nitro-N-nitrosoguanidine; ELISA, enzyme-linked immunosorbent assay; TUNEL, terminal dUTP nick-end labeling; DMEM, Dulbecco's modified Eagle's medium..


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES


1. Ludwig, A., Behnke, B., Holtlund, J., and Hilz, H. (1988) J. Biol. Chem. 263, 6993-6999[Abstract/Free Full Text]
2. de Murcia, G., Ménissier-de Murcia, J., and Schreiber, V. (1991) BioEssays 13, 455-462[Medline] [Order article via Infotrieve]
3. Althaus, F. R., and Richter, C. (1987) ADP-ribosylation of Proteins: Enzymology and Biological Significance , pp. 3-113, Springer-Verlag, Berlin
4. Lindahl, T., Satoh, M. S., Poirier, G. G., and Klungland, A. (1995) Trends Biochem. Sci. 20, 405-411[CrossRef][Medline] [Order article via Infotrieve]
5. Zahradka, P., and Ebisuzaki, K. (1982) Eur. J. Biochem. 127, 579-585[Abstract]
6. Satoh, M. S., and Lindahl, T. (1992) Nature 356, 356-358[CrossRef][Medline] [Order article via Infotrieve]
7. Vodenicharov, M. D., Sallmann, F. R., Wang, Z.-Q., Satoh, M. S., and Poirier, G. G. (2000) Nucleic Acids Res. 28, 3887-3896[Abstract/Free Full Text]
8. Simbulan-Rosenthal, C. M., Haddad, B. R., Rosenthal, D. S., Weaver, Z., Coleman, A., Luo, R., Young, H. M., Wang, Z. Q., Ried, T., and Smulson, M. E. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 13191-13196[Abstract/Free Full Text]
9. Dantzer, F., Nasheuer, H. P., Vonesch, J. L., de Murcia, G., and Menissier-de Murcia, J. (1998) Nucleic Acids Res. 26, 1891-1898[Abstract/Free Full Text]
10. Simbulan-Rosenthal, C. M., Rosenthal, D. S., Boulares, A. H., Hickey, R. J., Malkas, L. H., Coll, J. M., and Smulson, M. E. (1998) Biochemistry 37, 9363-9370[CrossRef][Medline] [Order article via Infotrieve]
11. Kannan, P., Yu, Y., Wankhade, S., and Tainsky, M. A. (1999) Nucleic Acids Res. 27, 866-874[Abstract/Free Full Text]
12. Meisterernst, M., Stelzer, G., and Roeder, R. G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2261-2265[Abstract/Free Full Text]
13. Anderson, M. G., Scoggin, K. E., Simbulan-Rosenthal, C. M., and Steadman, J. A. (2000) J. Virol. 74, 2169-2177[Abstract/Free Full Text]
14. Fakan, S., Leduc, Y., Lamarre, D., Brunet, G., and Poirier, G. G. (1988) Exp. Cell Res. 179, 517-526[Medline] [Order article via Infotrieve]
15. Desnoyers, S., Kaufmann, S. H., and Poirier, G. G. (1996) Exp. Cell Res. 227, 146-153[CrossRef][Medline] [Order article via Infotrieve]
16. Kaufmann, S. H., Brunet, G., Talbot, B., Lamarr, D., Dumas, C., Shaper, J. H., and Poirier, G. (1991) Exp. Cell Res. 192, 524-535[Medline] [Order article via Infotrieve]
17. Vispé, S., Yung, T. M. C., Ritchot, J., Serizawa, H., and Satoh, M. S. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 9886-9891[Abstract/Free Full Text]
18. Kaufmann, S. H. (1989) Cancer Res. 49, 5870-5878[Abstract]
19. Duriez, P. J., and Shah, G. M. (1997) Biochem. Cell Biol. 75, 337-349[CrossRef][Medline] [Order article via Infotrieve]
20. Lazebnik, Y. A., Kaufmann, S. H., Desnoyers, S., Poirier, G. G., and Earnshaw, W. C. (1994) Nature 371, 346-347[CrossRef][Medline] [Order article via Infotrieve]
21. Halappanavar, S. S., Rhun, Y. L., Mounir, S., Martins, L. M., Huot, J., Earnshaw, W. C., and Shah, G. M. (1999) J. Biol. Chem. 274, 37097-37104[Abstract/Free Full Text]
22. Oliver, F. J., de la Rubia, G., Rolli, V., Ruiz-Ruiz, M. C., de Murcia, G., and Murcia, J. M. (1998) J. Biol. Chem. 273, 33533-33539[Abstract/Free Full Text]
23. Herceg, Z., and Wang, Z. Q. (1999) Mol. Cell. Biol. 19, 5124-5133[Abstract/Free Full Text]
24. Boulares, A. H., Yakovlev, A. G., Ivanova, V., Stoica, B. A., Wang, G., Iyer, S., and Smulson, M. (1999) J. Biol. Chem. 274, 22932-22940[Abstract/Free Full Text]
25. Smulson, M. E., Pang, D., Jung, M., Dimtchev, A., Chasovskikh, S., Spoonde, A., Simbulan-Rosenthal, C., Rosenthal, D., Yakovlev, A., and Dritschilo, A. (1998) Cancer Res. 58, 3495-3498[Abstract]
26. Duriez, P. J., Desnoyers, S., Hoflack, J. C., Shah, G. M., Morelle, B., Bourassa, S., Poirier, G. G., and Talbot, B. (1997) Biochim. Biophys. Acta 1334, 65-72[Medline] [Order article via Infotrieve]
27. Manley, J. L., Fire, A., Samuels, M., and Sharp, P. A. (1983) Methods Enzymol. 101, 568-582[Medline] [Order article via Infotrieve]
28. Satoh, M. S., Poirier, G. G., and Lindahl, T. (1993) J. Biol. Chem. 268, 5480-5487[Abstract/Free Full Text]
29. Serizawa, H., Makela, T. P., Conaway, J. W., Conaway, R. C., Weinberg, R. A., and Yung, R. A. (1995) Nature 374, 280-282[CrossRef][Medline] [Order article via Infotrieve]
30. Shilatifard, A., Lane, W. S., Jackson, K. W., Conaway, R. C., and Conaway, J. W. (1996) Science 271, 1873-1876[Abstract]
31. D'Silva, I., Pelletier, J. D., Lagueux, J., D'Amours, D., Chaudhry, M. A., Weinfeld, M., Lees-Miller, S. P., and Poirier, G. G. (1999) Biochim. Biophys. Acta 1430, 119-126[Medline] [Order article via Infotrieve]
32. Satoh, M. S., and Hanawalt, P. C. (1996) Nucleic Acids Res. 24, 3576-3582[Abstract/Free Full Text]
33. Uptain, S. M., Kane, C. M., and Chamberlin, M. J. (1997) Annu. Rev. Biochem. 66, 117-172[CrossRef][Medline] [Order article via Infotrieve]
34. Ohgushi, H., Yoshihara, K., and Kamiya, T. (1980) J. Biol. Chem. 255, 6205-6211[Abstract/Free Full Text]
35. Wang, Z. Q., Stingl, L., Morrison, C., Jantsch, M., Los, M., Schulze-Osthoff, K., and Wagner, E. F. (1997) Genes Dev. 11, 2347-2358[Abstract/Free Full Text]
36. Le Rhun, Y., Kirkland, J. B., and Shah, G. M. (1998) Biochem. Biophys. Res. Commun. 245, 1-10[CrossRef][Medline] [Order article via Infotrieve]
37. de Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., Walztinger, C., Chambon, P., and de Murcia, G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7303-7307[Abstract/Free Full Text]
38. Decker, P., Isenberg, D., and Muller, S. (2000) J. Biol. Chem. 275, 9043-9046[Abstract/Free Full Text]
39. Molinete, M., Vermeulen, W., Bürkle, A., Ménissier-de Murcia, J., Küpper, J. H., Hoeijmakers, J. H. J., and de Murcia, G. (1993) EMBO J. 12, 2109-2118[Abstract]
40. Szabo, C., and Dawson, V. L. (1998) Trends Pharmacol. Sci. 19, 287-298[CrossRef][Medline] [Order article via Infotrieve]
41. Ha, H. C., and Snyder, S. H. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 13978-13982[Abstract/Free Full Text]
42. Kim, J. W., Kim, K., Kang, K., and Joe, C. O. (2000) J. Biol. Chem. 275, 8121-8125[Abstract/Free Full Text]
43. Kim, J. W., Won, J., Sohn, S., and Joe, C. O. (2000) J. Cell Sci. 113, 955-961[Abstract/Free Full Text]
44. Rosen, A., and Casciola-Rosen, L. (1997) J. Cell. Biochem. 64, 50-54[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.